COMMUNIQUÉS West-GlobeNewswire

ENvue Issues Stockholder Letter & Provides Corporate Update
16/04/2026
TYLER, Texas, April 16, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive [...]
Evaxion concludes Annual General Meeting
16/04/2026
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today [...]
Purisaki Berberine Patches 2026 | Effective Weight Loss For Women Lose 12+ lbs per Month Read Benefits, Ingredients, Side Effects, Lunch in USA.
16/04/2026
Purisaki Patches For Weight loss | Read Berberine weight loss consumer reports, Benefits, Side Effects, Price & Purisaki Berberine patches where to buy? New York City, April 16, 2026 (GLOBE NEWSWIRE) -- Introducing [...]
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
16/04/2026
TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based [...]
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
16/04/2026
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diagnoses in the U.S. [...]
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
16/04/2026
-- Partnership with AMI Technologies Positions FemaSeed ® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, April 16, 2026 (GLOBE NEWSWIRE) -- Femasys [...]
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
16/04/2026
First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025 +2.2% at actual rates impacted by significant currency headwinds Balanced growth in both segments : companion animal [...]
Virbac: forte croissance de +7,7 % au premier trimestre 2026 à pcc, portée par la croissance à deux chiffres de nos plateformes prioritaires Supercharge⁴
16/04/2026
Le chiffre d'affaires du premier trimestre 2026 a atteint 384 M€ : +7,7 % à taux de change et périmètre constants par rapport au T1 2025. +2,2 % à taux réels, impactés par des effets de change significativement [...]
Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
16/04/2026
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thursday, May 7, 2026 [...]
Elicio Therapeutics Reports Inducement Grants
16/04/2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Helsinn appoints Giacomo Braglia to the Board of Directors
16/04/2026
Lugano, Switzerland – April 16 th , 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, is pleased to announce the appointment of [...]
MIMEDX Announces Restructuring and Cost Reduction Initiative
16/04/2026
Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost [...]
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
16/04/2026
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate The Medicare Administrative Contractor (MAC) responsible for processing inFoods® [...]
Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026
16/04/2026
FREIBURG, Germany and ROSCREA, Ireland, April 16, 2026 (GLOBE NEWSWIRE) -- Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and [...]
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
16/04/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on [...]
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
16/04/2026
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large [...]
Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design
16/04/2026
International Red Dot Jury recognizes Nanox.ARC X for design excellence that brings advanced 3D tomosynthesis imaging into a wider range of clinical settings PETACH TIKVA, ISRAEL - 1 6 April , 2026 - Nanox Imaging Ltd [...]
Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026
16/04/2026
First-in-class, covalent, oral small molecule inhibitor targeting IRF5 IRF5 is a genetically validated driver of autoimmune diseases, including systemic lupus erythematosus, Sjögren’s disease, and rheumatoid arthritis [...]
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
16/04/2026
TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]

Pages